Ken Griffin Bristol Myers Squibb CO Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$39.66 - $51.75 $56.3 Million - $73.5 Million	1,420,100 Added 24.83%	7,139,900 $369 Million
Q2 2024 Aug 14, 2024	BUY	$40.25 - $52.99 $73.3 Million - $96.5 Million	1,821,500 Added 46.73%	5,719,800 $238 Million
Q1 2024 May 15, 2024	BUY	$47.98 - $54.4 $52 Million - $58.9 Million	1,083,400 Added 38.49%	3,898,300 $211 Million
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $19.5 Million - $23.2 Million	401,600 Added 16.64%	2,814,900 $144 Million
Q3 2023 Nov 14, 2023	BUY	$57.89 - $64.73 $52.7 Million - $58.9 Million	909,700 Added 60.5%	2,413,300 $140 Million
Q2 2023 Aug 14, 2023	SELL	$63.71 - $70.74 $14.4 Million - $16 Million	-226,800 Reduced 13.11%	1,503,600 $96.2 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $121 Million - $137 Million	-1,835,900 Reduced 51.48%	1,730,400 $120 Million
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $38.3 Million - $45.4 Million	560,000 Added 18.63%	3,566,300 $257 Million
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $124,241 - $73.4 Million	-955,700 Reduced 24.12%	3,006,300 $214 Million

2,532

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $123B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.